Navigation Links
Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR

decision to advance KOS-1584 into Phase 2 trials in solid tumors. The Phase 2 program is anticipated to begin in the second half of 2007.

Data on KOS-1803 were presented in a poster titled, "KOS-1803: A New, Rationally Designed Epothilone Analog with an Improved Pharmacological Profile and Efficacy in Xenograft Mouse Models," at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, CA.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 (R1645) is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of th
'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
(Date:7/30/2015)...   Gaumard® Scientific Company today announced ... first operating system to support an entire family ... Gaumard users. UNI® version 2.27.21.0 adds enhanced functionality ... as well as improvements to laboratory functions, patient ... as EtCO 2 .  First ...
(Date:7/30/2015)... 2015   Sentrian , the Remote Patient ... recently received confirmation from the Food & Drug ... solution meets the definition of a "medical device" ... Discretion." The designation identifies medical ... regulatory requirements at this time" and clears the ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... Effectiveness of Autologous Therapy, DUSSELDORF, Germany, ... two-year,representative study of knee osteoarthritis, published in ... safety and effectiveness of Orthokine therapy, in ... blood are,injected into the arthritic joint., ...
... New Therapeutic Platform in Patients with Cystoid Macular ... ... Aug. 5 Icon Bioscience, Inc., (IBI),a privately held ophthalmic pharmaceutical ... clinical trial to assess the,safety and efficacy of its lead product, ...
Cached Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... 31, 2015 , ... New Energy Works Timberframers invites the public to join ... 15th, 2015 from 9am – 12pm. Timber frame raisings are special, celebrating ... community as the culmination of months of effort, planning, fundraising, and dreaming takes shape. ...
(Date:7/31/2015)... ... , ... “ Crack’em ” was featured on NewsWatch as part of its ... Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and ... Cooking can be a very messy experience, especially when cracking eggs. Cracking an egg ...
(Date:7/31/2015)... ... ... Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, August 22nd ... duathlon is a 2 mile run, 13 mile bike ride, and a 3 mile run. ... and a 3 mile run. Heels & Wheels is sponsored by Mayo Clinic System ...
(Date:7/31/2015)... ... July 31, 2015 , ... David Gilpin, ... website to inform potential Nashville area sinus sufferers about the benefits ... to determine if someone is a good candidate for Balloon Sinuplasty. The questionnaire ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Make Less Mess while Cooking with Crack’em 2Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3
... of Pennsylvania School of Medicine and other study sites ... non-invasive technique that excites neurons in the brain via ... safe and effective, non-drug treatment with minimal side effects ... treatment options without benefit. , This study ...
... generates green pods while a variant of that gene ... helped Gregor Mendel, the 19th century Austrian priest and ... are focused on the strange ability of some genes ... ways. , In order to better understand this phenomenon ...
... researchers have identified structural damage to the lungs caused ... the study, conducted by researchers at the University of ... Hospital of Philadelphia in Pennsylvania, were presented today at ... America (RSNA). , Its long been hypothesized that prolonged ...
... of Australias leading medical,research institutes, unveiled a powerful ... cutting edge in medical technology and microscopy, the ... scientists at the Centenary Institute,unprecedented access to the ... and molecular,level., The Centenary Institute is equally excited ...
... CARLSBAD, Calif., Nov. 26 Visage Imaging, a,wholly ... MRCY ),announced an agreement with Siemens Medical ... solutions to hospitals and imaging,centers worldwide., Siemens ... into its SIENET Magic product line. This unique ...
... Ohio, Nov. 26 Understand how improving ... That,s the message behind,the new book "REM ... by Timothy J. Walter, M.D., a sleep ... (Lotus Magnus, August,2007, ISBN-13: 978-1604022377, $19.95) integrates ...
Cached Medicine News:Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:Flip-flopping gene expression can be advantageous 2Health News:Novel MRI technique shows secondhand smoke damages lungs 2Health News:World class technology and talent battle cancer at the Centenary Institute 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 3Health News:Understand How Sleep Impacts Learning and Memory 2
The Vivid e delivers everything you need in a compact echo system, like complete cardiovascular functionality, a comprehensive cardiac measurement and analysis package, and full shared service capabi...
BonePlast is a fast resorbing, osteoconductive bone void filler. By delivering a high dose of calcium to the operative site, BonePlast helps build new bone during the healing process. Packaged in a c...
... The patented telescoping plate ... an anterior plate and vertebral ... design eliminates the need for ... generous amount of bone graft ...
"Small" redefined for Holter recorders!...
Medicine Products: